company background image
STX

Shield Therapeutics AIM:STX Stock Report

Last Price

UK£0.063

Market Cap

UK£34.9m

7D

-3.8%

1Y

-82.6%

Updated

05 Feb, 2023

Data

Company Financials +

STX Stock Overview

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs.

STX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

Shield Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shield Therapeutics
Historical stock prices
Current Share PriceUK£0.063
52 Week HighUK£0.37
52 Week LowUK£0.055
Beta1.18
1 Month Change-3.08%
3 Month Change-25.88%
1 Year Change-82.62%
3 Year Change-96.10%
5 Year Change-81.74%
Change since IPO-95.99%

Recent News & Updates

Recent updates

Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

Mar 02
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

May 06
What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

Mar 15
Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Jan 27
We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Dec 15
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Shareholder Returns

STXGB PharmaceuticalsGB Market
7D-3.8%0.4%1.8%
1Y-82.6%4.1%-3.7%

Return vs Industry: STX underperformed the UK Pharmaceuticals industry which returned 4.1% over the past year.

Return vs Market: STX underperformed the UK Market which returned -3.7% over the past year.

Price Volatility

Is STX's price volatile compared to industry and market?
STX volatility
STX Average Weekly Movement10.6%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement5.1%
10% most volatile stocks in GB Market11.0%
10% least volatile stocks in GB Market2.7%

Stable Share Price: STX is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: STX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
200815Greg Madisonhttps://www.shieldtherapeutics.com

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company’s lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.

Shield Therapeutics plc Fundamentals Summary

How do Shield Therapeutics's earnings and revenue compare to its market cap?
STX fundamental statistics
Market CapUK£34.92m
Earnings (TTM)-UK£23.83m
Revenue (TTM)UK£3.07m

11.4x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STX income statement (TTM)
RevenueUK£3.07m
Cost of RevenueUK£1.45m
Gross ProfitUK£1.62m
Other ExpensesUK£25.45m
Earnings-UK£23.83m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.043
Gross Margin52.62%
Net Profit Margin-776.64%
Debt/Equity Ratio0%

How did STX perform over the long term?

See historical performance and comparison